Samsung Bioepis Co., Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Samsung Bioepis Co., Ltd.
Renewed efforts are needed to educate healthcare industry stakeholders about biosimilars, Samsung Bioepis has insisted, as the firm published a white paper detailing deficiencies in understanding on the part of patients and healthcare professionals.
Samsung Bioepis has announced that its SB16 biosimilar denosumab rival to Amgen’s Prolia has progressed to Phase III trials.
Amgen will be able to launch its US Soliris biosimilar around two years ahead of patent expiry under a settlement agreement. The brand’s manufacturer, Alexion, discussed the threat as AstraZeneca pounced with a $39bn takeover agreement.
Keeping Track: US FDA Approves Zokinvy, Defers Liso-Cel, Declines ALKS 3831 And Zimhi; Two Biosimilars Filed
The latest drug developments news and highlights from the Pink Sheet’s US FDA Performance Tracker
- Large Molecule
- Other Names / Subsidiaries
- Samsung Biologics
- Samsung Bioepis JV
- Samsung Bioepis BR Pharmaceutical LTDA